Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

Addis, Victoria; Miller-Ellis, Eydie

doi:10.2147/opth.s156038

Cited by 15 publications

(12 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LBN is the first NO-donating prostaglandin F2-alpha analog on the market ( Addis and Miller-Ellis, 2018 ; Hoy, 2018a ; Mehran et al, 2020 ). LBN administered every evening (QD) exerted a significantly greater effect and it is safer than timolol 0.5% (BID) ( Kawase et al, 2016 ; Liu et al, 2016 ; Weinreb et al, 2016 ; Weinreb et al, 2018 ).…”

Section: Topical Monotherapy Agentsmentioning

confidence: 99%

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Wang

Cao²,

Jiang³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Glaucoma is one of the most common causes of blindness, thus seriously affecting people’s health and quality of life. The topical medical therapy is as the first line treatment in the management of glaucoma since it is inexpensive, convenient, effective, and safe. This review summarizes and compares extensive clinical trials on the topical medications for the treatment of glaucoma, including topical monotherapy agents, topical fixed-combination agents, topical non-fixed combination agents, and their composition, mechanism of action, efficacy, and adverse effects, which will provide reference for optimal choice of clinical medication. Fixed-combination therapeutics offer greater efficacy, reliable security, clinical compliance, and tolerance than non-fixed combination agents and monotherapy agents, which will become a prefer option for the treatment of glaucoma. Meanwhile, we also discuss new trends in the field of new fixed combinations of medications, which may better control IOP and treat glaucoma.

show abstract

Section: Topical Monotherapy Agentsmentioning

confidence: 99%

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Wang

Cao²,

Jiang³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…A Phase IIb dose-finding study was completed in 2018 [NCT03216902]. The release of NO results in further IOP-lowering effect through increased trabecular meshwork outflow by cAMP-mediated relaxation of trabecular meshwork cells ( 58 , 59 ). Non-IOP related physiological functions of NO may also be important in terms of glaucoma pathophysiology and treatment.…”

Section: Discussionmentioning

confidence: 99%

“…The compounds listed in Figure 4 are discussed below. (58,59). Non-IOP related physiological functions of NO may also be important in terms of glaucoma pathophysiology and treatment.…”

Section: Discussion Pipeline Drugs and Tendencies In Glaucoma Clinical Trialsmentioning

confidence: 99%

Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development

et al. 2021

View full text Add to dashboard Cite

Purpose: To investigate the trends and progresses in glaucoma research by searching two major clinical trial registries; clinicaltrials.gov, and Australianclinicaltrials.gov.au.Methods: All clinical trials with glaucoma covered by Clinicaltrials.gov, and Australianclinicaltrials.gov.au starting the study before 1 January 2021 were included. Trials evaluating glaucoma treatment were separated from non-treatment trials and divided into three major categories: “laser treatment,” “surgical treatment,” and “medical treatment.” In the category of “medical treatment,” new compounds and their individual targets were identified and subcategorized according to treatment strategy; intraocular pressure (IOP)-lowering, neuroprotective or vascular. The phase transition success rates were calculated.Results: One-thousand five hundred and thirty-seven trials were identified. Sixty-three percent (n = 971) evaluated glaucoma treatment, of which medical treatment accounted for the largest proportion (53%). The majority of medical trials evaluated IOP-lowering compounds, while trials with neuroprotective or vascular compounds accounted for only 5 and 3%, respectively. Eighty-eight new compounds were identified. Phase I, II, and III transition success rates were 63, 26, and 47%, respectively.Conclusion: The number of clinical trials in glaucoma research has increased significantly over the last 30 years. Among the most recently evaluated compounds, all three main treatment strategies were represented, but clinical trials in neuroprotection and vascular modalities are still sparse. In addition to traditional medicines, dietary supplements and growth factors are assessed for a potential anti-glaucomatous effect. Phase II and III success rates were below previously reported success rates for all diseases and ophthalmology in general. A stricter phenotyping of patients can improve the success rates in glaucoma and ophthalmological research and gain a better understanding of responders and non-responders.

show abstract

“…Increases uveoscleral outflow. One plausible mechanism may involve induction of metalloproteinases in the ciliary body, and breakdown of the extracellular matrix, with subsequent reduction in outflow resistance through the uveoscleral pathway (traditional PG analogues: bimatoprost, latanoprost, and travoprost) [28,[54][55][56][57].…”

Section: Pg Analoguesmentioning

confidence: 99%

Pharmaceutical treatment of primary open angle glaucoma

Al-Namaeh¹

2021

Med Hypothesis Discov Innov Optom

View full text Add to dashboard Cite

Background: Glaucoma is a progressive, irreversible optic neuropathy that results in serious vision loss and blindness. This review aimed to summarize key concepts of primary open angle glaucoma (POAG) pharmaceutical treatment trials over the last decade. Methods: We searched PubMed/MEDLINE and clinicaltrials.gov from January 1, 2010, to August 31, 2020, using the key words “POAG” and “Ocular topical therapeutics”. This search yielded 77 and 120 papers, respectively. Results: Thirty-three records were compatible with our inclusion criteria. Pharmaceutical treatment is a common intervention in POAG for lowering IOP. Prostaglandin (PG) analogues are most commonly recommended as initial medical therapy, which are administrated either as a monotherapy or in combination with other IOP-lowering classes of medications. Alternative therapies, such as ?-blockers, ?-2 adrenergic receptor agonists, and topical carbonic anhydrase inhibitors, have been used in combination or as a monotherapy. Rho-kinase inhibitors, such as netarsudil 0.02%, AR-13324 0.02%, and ripasudil are new IOP-lowering medications. Despite IOP reduction, there is a significant number of patients with POAG that may experience disease progression, and the risk of blindness over the long term is considerable. Conclusions: Clinical trials have indicated that pharmaceutical treatment of POAG is effective and safe. In addition, the new novel Rho-kinase inhibitors have shown significant IOP reduction. The new fixed combinations have also yielded significant reductions in IOP. POAG is a cause of irreversible vision loss, if not diagnosed and treated early. The condition is likely to progress in a significant number of patients, with a considerable risk of blindness in the long-term. How to cite this article: Al-Namaeh M. Pharmaceutical treatment of primary open angle glaucoma. Med Hypothesis Discov Innov Optom. 2021 Spring; 2(1): 8-17. DOI: https://doi.org/10.51329/mehdioptometry120

show abstract

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

Cited by 15 publications

References 41 publications

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development

Pharmaceutical treatment of primary open angle glaucoma

Contact Info

Product

Resources

About